Document:

Exhibit

Exhibit 10.4

EXECUTION VERSION

CONTRIBUTION AGREEMENT
CONTRIBUTION AGREEMENT (this “Agreement”), dated as of October 31, 2015, by and between NorthStar Realty Europe Corp., a Maryland corporation (“NRE”), and NorthStar Realty Finance Corp., a Maryland corporation (“NRE”).
RECITALS
WHEREAS, NRE and NRF will be parties to a Separation Agreement, dated as of the date hereof (the “Separation Agreement”), pursuant to which NRF will (i) spin-off its European commercial real estate business into a separate publicly traded company, NRE (the “Spin-Off”), and (ii) distribute to the Recipients (as defined in the Separation Agreement) all of the outstanding common stock of NRE in accordance with the terms of the Distribution (as defined in the Separation Agreement);
WHEREAS, in connection with the transactions described on Annex I hereto (the “Separation Transactions”) and to further capitalize NRE, NorthStar Realty Finance Limited Partnership (the “NRF Operating Partnership”) has transferred (i) all of the equity interests in certain of its subsidiaries and (ii) $250 million in cash, to NorthStar Realty Europe Limited Partnership (the “NRE Operating Partnership”) on or prior to the date hereof pursuant to the contribution agreements attached on Annex II hereto;
WHEREAS, the NRF Operating Partnership has distributed all of the partnership common units of the NRE Operating Partnership to NRF and holders of certain equity interests in the NRF Operating Partnership, causing approximately 99% of the partnership common units of the NRE Operating Partnership to be held by NRF and approximately 1% of the partnership common units of the NRE Operating Partnership to be held by the holders of certain equity interests in the NRF Operating Partnership;
WHEREAS, NRF desires to contribute to NRE all of the outstanding partnership common units of the NRE Operating Partnership that NRF currently owns in exchange for additional shares of NRE’s common stock (the “Contribution”); and
WHEREAS, in consideration of the substantial actions and expense that have been taken in connection with the Spin-Off, the parties hereto are entering into this Agreement to bind each other to effect the Contribution as part of the Separation Transactions.
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are acknowledged by this Agreement, the parties agree as follows:
1.Contribution and Issuance of NRE Shares.  In connection with the Separation Transactions, NRF hereby agrees to contribute and NRE agrees to accept, effective as of 11:03 p.m. New York City time on the date of this Agreement, all of the outstanding partnership common units of the NRE Operating Partnership that NRF currently owns.  In exchange for the Contribution, NRE hereby agrees to issue to NRF a number of shares of NRE common stock 

equal to one share of NRE common stock for every six shares of NRF common stock that will be outstanding as of 5:01 PM on October 22, 2015, minus the number of shares of NRE common stock owned by NRF prior to such issuance. It is the intention of the parties hereto that after the shares of NRE common stock are issued to NRF pursuant to this section, NRF shall own an amount of NRE common stock that is equivalent to one-sixth of the number of shares of common stock of NRF that are outstanding as of 5:01 PM on October 22, 2015. 
2.    Further Assurances. Each party hereto agrees to take such further actions as may be reasonably necessary to effect the transactions contemplated by this Agreement, including the Separation Transactions, and cooperate in all matters relating to the Separation Transactions. Such cooperation shall include, but not be limited to, obtaining all consents, licenses, sublicenses or approvals necessary for such party to effect the Separation Transactions.
3.    Complete Agreement; Construction. This Agreement, including the Annex hereto, shall constitute the entire agreement between the parties with respect to the subject matter hereof and shall supersede all previous negotiations, commitments and writings with respect to such subject matter.
4.    Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when one or more such counterparts have been signed by each of the parties hereto and delivered to each other party.
5.    Waivers. The failure of any party to require strict performance by any other party of any provision in this Agreement shall not waive or diminish that party’s right to demand strict performance thereafter of that or any other provision hereof.
6.    Amendments. This Agreement may not be modified or amended except by an agreement in writing signed by each of the parties hereto.
7.    Assignment. This Agreement shall not be assignable, in whole or in part, directly or indirectly, by any party hereto without the prior written consent of each other party hereto, and any attempt to assign any rights or obligations arising under this Agreement without such consent shall be void; provided that any party may assign this Agreement to a purchaser of all or substantially all of the properties and assets of such party so long as such purchaser expressly assumes, in a written instrument in form reasonably satisfactory to the non-assigning parties, the due and punctual performance or observance of every agreement and covenant of this Agreement on the part of the assigning party to be performed or observed.
8.    Third-Party Beneficiaries. This Agreement is solely for the benefit of the parties hereto and shall not be deemed to confer upon any other person any remedy, claim, liability, reimbursement, cause of action or other right of any kind.
9.    Titles and Headings. Titles and headings to Sections herein are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.

-2-

SC1:3919561.4

10.    Annex. The Annex shall be construed with and as an integral part of this Agreement to the same extent as if the same had been set forth verbatim herein.
11.    Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN THE STATE OF NEW YORK AND WITHOUT REGARD TO ITS CHOICE OF LAW PRINCIPLES.
12.    Waiver of Jury Trial. The parties hereto hereby irrevocably waive any and all right to trial by jury in any legal proceeding arising out of or related to this Agreement.
13.    Specific Performance. From and after the Distribution Date (as defined in the Separation Agreement), in the event of any actual or threatened default in, or breach of, any of the terms, conditions and provisions of this Agreement, the parties agree that the party to this Agreement who is or is to be thereby aggrieved shall have the right to specific performance and injunctive or other equitable relief of its rights under this Agreement, in addition to any and all other rights and remedies at law or in equity, and all such rights and remedies shall be cumulative. The parties agree that, from and after the Distribution Date, the remedies at law for any breach or threatened breach of this Agreement, including monetary damages, are inadequate compensation for any loss, that any defense in any action for specific performance that a remedy at law would be adequate is hereby waived, and that any requirements for the securing or posting of any bond with such remedy are hereby waived.
14.    Severability. In the event any one or more of the provisions contained in this Agreement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and therein shall not in any way be affected or impaired thereby. The parties hereto shall endeavor in good faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions, the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.
[Signature Page Follows]

-3-

SC1:3919561.4

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.
	
		
	NORTHSTAR REALTY EUROPE CORP.

	/s/ Trevor K. Ross

	Name:
	Trevor K. Ross

	Title:
	General Counsel and Secretary

	 

	NORTHSTAR REALTY FINANCE CORP.

	/s/ Ronald J. Lieberman

	Name:
	Ronald J. Lieberman

	Title:
	Executive Vice President and General Counsel

	 

[Signature Page to Contribution Agreement]

Annex I
Separation Transactions
		
	1.
	NRF contributes its 5.1% ownership interest in Trias Holdings-T(US), LLC and its 5.1% ownership interest in Prime Holdings-T(US), LLC to NRF Operating Partnership pursuant to the contribution agreement included in Annex II to the Contribution Agreement.

		
	2.
	NRF Operating Partnership contributes (i) all of its rights, title, and interest in Trias Holdings-T(US), LLC, Prime Holdings-T(US), LLC, Symbol Holdings-T(US), LLC and Dukes Court-T(UK), LLC, and (ii) $250 million in cash, to NRE Operating Partnership in exchange for a number of partnership common units in NRE Operating Partnership calculated pursuant to the contribution agreement included in Annex II to the Contribution Agreement. 

		
	3.
	NRF Operating Partnership distributes partnership common units of NRE Operating Partnership, pro rata, to NRF and holders of certain equity interests in NRF Operating Partnership based on their percentage ownership in NRF Operating Partnership.

		
	4.
	NRF contributes all of the outstanding common units of the NRE Operating Partnership that it owns to NRE in exchange for such number of shares of NRE common stock equal to one share of NRE common stock for every six shares of NRF common stock that will be outstanding as of 5:01 PM on October 22, 2015, minus the number of shares of NRE owned by NRF prior to such issuance.

		
	5.
	NRF distributes one share of NRE common stock, par value $0.01 per share, for every six shares of NRF common stock held by the Record Holders (as defined in the Separation Agreement).EXHIBIT 10.19

 Exhibit 10.19
 

 Agreement for the Rendering of Services
 

 THIS AGREEMENT for the rendering of services (the “Agreement”) is entered into as of November 1, 2015 ("Effective Date") by and between Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (“Yissum”) and  Accurexa, Inc. (“Company”).  
 

 Yissum and the Company hereby agree to all of the following terms and conditions:
 

 1.
 The Services: The Company hereby requests that the following laboratory services be performed via Yissum: Polymeric formulation of a combination of carmustine and temozolomide for sustained local administration to a solid tumor (the “Services”). The objectives and specifications of the Services shall be detailed in the protocol attached hereto as Appendix A (the "Service Protocol"), which shall constitute an integral part of this Agreement. The Company shall provide, at no cost to Yissum or the Researcher, amount of materials sufficient to complete the Service Protocol. 
 

 2.
 Time Schedule: The Services are to be performed in accordance with the following time schedule:
 Start on: ____________
 Complete on: ____________ (the “Service Period”). 
 

 3.
 The Researcher: The Services will be performed by or under the control and supervision of Prof. Avi Domb or such other qualified person as may be determined and appointed from time to time by Yissum (the “Researcher”).
 

 4.
 The Scientific Report: The scientific report that will be required as a result of the Services rendered will be presented directly to the Company by the Researcher within 14 (fourteen) days of the end of the Service Period (the “Scientific Report”). The Company acknowledges that no financial report will be given by Yissum.
 

 5.
 The Consideration: In consideration for provision of the Services and the Scientific Report, the Company shall be obligated to pay Yissum the total sum of ___________ (inclusive of overhead), plus any applicable value added tax (the "Service Fee"). The Company shall pay the Service Fee on the following dates: 
 

 i.
 ___________ on the Effective Date
 ii.
 ___________ [Date]
 iii.
 ___________ upon submission of the final Scientific Report
 

 Payment shall be made upon the presentation of an invoice.  In the event that the Company fails to pay an invoiced amount in a timely manner, Yissum shall be entitled to add to the unpaid invoiced amount an additional amount equal to annualized interest of Prime (as determined by the Bank of Israel) plus 5%, together with exchange rate differentials, if any. 
 

 6.
 Intellectual Property:  It is hereby agreed that the Company retains ownership in its Confidential Information, as defined below, and all intellectual property rights that are discovered or developed during the course of the provision of the Services or under the Service Protocol, or as a result thereof. In addition, any intellectual property belonging to either the Company or Yissum prior to the execution of this Agreement will remain the sole property of either the Company or Yissum, respectively.
 

 All data generated from the provision of the Services, including the Scientific Report, which are specifically required and contemplated under the Service Protocol, shall be owned by the Company upon full payment of the Service Fee (the “Company Data”).
 

 Notwithstanding the above, all rights, title and interest in all inventions, discoveries, methods, new uses, processes or compounds, whether or not capable of registration, and any patent applications or patents based thereon, discovered or developed outside the scope of the Services or the Service Protocol during the course of the provision of the Services or as a result thereof, shall be solely owned by Yissum (the “Yissum Inventions”). Yissum shall notify the Company in writing of the Yissum Inventions directly related to the subject matter of the Services, and 
 

 
 

 

 the Company shall have a right of first review for a period of 30 days from the date it received such notification to evaluate whether it wishes to license any of the disclosed Yissum Inventions. Should the Company give Yissum notice within the aforesaid 30-day period, it shall be entitled to an additional 90 days from the date such notice to negotiate commercial terms and execute a license agreement (the "Negotiation Period"). In the event (a) the Company shall notify Yissum that it does not wish to license any of the disclosed Yissum Inventions; or (b) the Company does not reply within the aforesaid 30-day period; or (c) the parties shall fail to execute a license agreement within the Negotiation Period, Yissum shall then be entitled to license such Yissum Inventions to any other third party without any obligation to the Company.
 

   7.
 Confidentiality: Yissum and the Researcher agree to maintain the confidentiality of any information disclosed to them by the Company in connection with the Services, which the Company identifies as confidential at the time of disclosure ("Confidential Information"), and not to make public any such Confidential Information without the prior written permission of the Company. This undertaking shall not apply to Confidential Information that is in the public domain at the time of disclosure or thereafter enters the public domain through no fault of Yissum or the Researcher; or that the Researcher can show, by contemporaneous written evidence, was already known to him at the time of disclosure; or that is provided to Yissum or the Researcher by a third party having no obligations of confidentiality to the Company. In addition, Yissum or the Researcher shall be entitled to disclose Confidential Information pursuant to a valid judicial or administrative order, provided that they shall provide prompt notice to the Company of their receipt of such an order to allow the Company to seek relief against such order.
 

   8.
 Publications:  The Researcher will be permitted to publish information regarding his/her technical work connected to the Services provided that he/she first submits the publication to the Company. The Company may reasonably withhold its consent to such publication solely to delete sensitive Company owned Confidential Information and to allow for the filing of patent applications or similar intellectual property protection on any of the Company’s intellectual property that might appear in the proposed publication, provided however that in no event will such Company consent be withheld for a period longer than 90 days from the day that the Researcher first submitted the said publication to the Company, after which time the publication will be automatically permitted.
 

 9.
 Use of Names: The Company shall not make any use of any kind of the name of the Researcher(s) and/or Yissum and/or the Hebrew University without the prior written consent of Yissum, which consent shall not be unreasonably withheld.
 

 10.
 Relationship of the Parties: The parties do not stand in a relationship of employer-employee. Such relationship shall be that of requester – independent contractor.
 

 11.
 Dispute Resolution: In all cases in which a dispute shall arise between the Company and Yissum in connection with this Agreement or any rights or obligations arising hereunder, a single arbitrator shall be chosen by mutual agreement to decide the dispute, and in the absence of mutual agreement, an arbitrator shall be appointed at the request of either party by the President of the Jerusalem District Court.  The arbitration and decision of the arbitrator shall be governed solely by Israeli substantive law, without application of Israeli procedural law requirements or any conflict of law principles, and shall be a final disposition of the matter, not subject to appeal. The arbitration proceedings shall take place in Jerusalem, Israel, and shall be conducted in the English language, unless the parties agree otherwise at the time of the arbitration. This section 10 shall be deemed an arbitration agreement for the purpose of the Israeli Arbitration Law, 1968.  
 

 12.
 Authorized Signatories: Signature by at least two authorized representatives of Yissum on this Agreement shall constitute Yissum’s approval and agreement to all that is written herein. The Company warrants that the person or persons signing this agreement is/are authorized to bind the Company.
 

 13.
 Disclaimer of Warranty, Liability and Indemnification: 
 

 (a)
 Nothing contained in this Agreement shall be construed as a warranty on the part of Yissum that any results or inventions will be achieved by the Services, or that the results of the Services, if any, are or will be of commercial or scientific value to the Company.
 

 (b)
 Yissum and the Hebrew University, and their respective parents, affiliates, officers, directors, employees, agents and contractors, (all such parties collectively: the “Indemnitees”), shall not be liable for any claims, actions, demands, losses, damages, costs and expenses (including without limitation legal fees) 
 

 
 

 

 (collectively: “Claims”) made, brought or suffered by the Company or by any third parties arising from any exploitation or use of the Services provided (including without limitation any Services work product and data).
 

 (c)
 In the event of any third party Claims are brought against any of the Indemnitees as set out above, the Company shall indemnify the relevant Indemnitees and hold them harmless from and against any and all such damages, liability, losses, costs and/or expenses.
 

 14.
 Termination:
 

 (a)
 Unless terminated in accordance with the provisions of this Agreement, this Agreement shall end at upon the presentation of the Scientific Report.
 

 (b)
 Each party shall be entitled to terminate this Agreement in the event of a breach by the other party of its obligations under this Agreement, including, but not limited to, any payment failure, which is not remedied by the breaching party within 30 days of receipt of written notice from the non-breaching party. 
 

 (c)
 If the Agreement is terminated prior to the end of the Service Period, all amounts paid under this Agreement up to the date of termination shall be considered as non-refundable.
 

 (d)
 Sections 6, 7, 8, 9, 11 and 13 shall survive termination of this Agreement.
 

 

 

 	 	
	 Accurexa, Inc. 
 113 Barksdale
 Newark, DE 19711
 USA
 

 

 By: /s/ George Yu_____________________
 

 Name: George Yu_____________________
 

 Title: President & CEO_________________
 

 Date: November 1, 2015________________ 
 

 

 

	 Yissum Research Development Company
 of the Hebrew University of Jerusalem Ltd.
 Hi-Tech Park, Edmond J. Safra Campus,
 Givat Ram, P.O.B 39135, Jerusalem 91390, Israel
 

 

 By: /s/ Itzik Goldwaser     and  /s/ Yaacov Michlin
 

 Name: Itzik Goldwaser             Yaacov Michlin
 

 Title : VP, Head of                     CEO
            Research Collaboration
 

 Date: November 1, 2015

	 Researcher’s Agreement:
 I the undersigned, Prof. Avi Domb, of the Hebrew University of Jerusalem, have reviewed, am familiar with and agree to all of the above terms and conditions. I hereby undertake to fully cooperate with Yissum in order to ensure its ability to fulfill its obligations hereunder, as set forth herein.
 

 Signature: /s/ Abraham Domb________________________      Date: November 1, 2015____________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}]]